Lung cancer is by far the leading cause of cancer deaths in the world. If not detected early, 80% of patients do not make it after five years. Dr. Aki Al-Zubaidi, an interventional pulmonologist, knew that the best way to beat the statistics is early detection. He wanted to identify all the patients in his own clinic who had a specific abnormality, or a spot on the lungs that could become a cancer.
Yet, flagging all these patients and trying to keep up with all of them became too overwhelming. He tried to look for a solution out there but found none. Thus, the idea of using a software to help with the early detection of lung cancer was born.
With the help of Christine Spraker, a serial entrepreneur, they developed a software that is focused on gathering, curating, and sharing healthcare information to make sure that the right data reaches the right people at the right time so that lives can be saved.
Let us hear from Dr. Aki Al-Zubaidi and Christine Spraker, Co-CEOs of Eon, as they share how Eon’s journey began, and how they continue to become the market leader in improving patient care and lowering healthcare costs all over the country.
Top Takeaways:
01:37 How Aki and Christine got connected
04:16 How did they get their first clients on board
05:33 How can incidental findings increase EBITDA?
06:35 What is Eon?
13:37 How cold-calling billionaires (and non-billionaires) paid off
14:58 What made them decide to inject more capital into their business
16:00 Aki & Christine’s big AHA’s in raising money for the business.
17:16 Why you should never leverage your mission or your core beliefs
25:12 Eon’s core mission
26:35 Why Eon is aiming for total market domination
28:39 Eon’s biggest advantage over their competitors
To get in touch with Dr. Aki Al-Zubaidi and Christine Spraker, go to their website https://eonhealth.com/
About the guests:
Dr. Akrum (Aki) Al-Zubaidi, Founder and Co-CEO
Aki is an Interventional Pulmonologist who has dedicated his career to pulmonary nodule management. His background in human genetics and oncology research made him realize that the way to have disruptive change is to combine innovation and action. Today, he is on a mission to close the gap between technological ability and healthcare implementation.
Christine Spraker, Co-CEO
Christine has more than 16 years of experience in the industry. As a domain expert, and having been touched by lung cancer loss herself, she continuously seeks improved outcomes for nodule and lung cancer patients. She has made it her mission to impact patient lives, and the providers who serve them, with improved technology and tools.